Overview

* Maravai Q2 revenue falls 31.7% yr/yr, meeting analyst expectations, per LSEG data

* Adjusted EPS and EBITDA miss analyst estimates, per LSEG data

* Co earlier announced restructuring for $50 mln annualized cost savings

Outlook

* Maravai withdraws 2025 revenue guidance amid leadership transition

* Company expects positive adjusted EBITDA by second half 2026

* Maravai targets $50 mln in annualized cost savings

* Restructuring charges estimated at $8-9 mln in H2 2025

Result Drivers

* REVENUE DECLINE - Nucleic Acid Production revenue fell 43.1% due to lack of high-volume CleanCap orders for vaccine programs

* RESTRUCTURING - Co targets over $50 mln in annualized cost savings through labor, facilities, capex and productivity initiatives

* BIOLOGICS SAFETY TESTING - Revenue grew 9.9% driven by demand for Host Cell Protein kits and MockV viral clearance kits

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Meet $47.40 $47.40

Revenue mln mln (12

Analysts

)

Q2 Miss -$0.08 -$0.07

Adjusted (11

EPS Analysts

)

Q2 EPS -$0.27

Q2 Miss -$10.40 -$8.39

Adjusted mln mln (9

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc ( MRVI ) is $5.00, about 56% above its August 8 closing price of $2.20

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)